glp-1 news 2025 november nov GLP-1 Receptor Agonist Market Growth Analysis As GLP-1 Drugs Go Mainstream,
Description
In the AMPLITUDE-O post-hoc analysis, the HR for MACE was 0.70 (95% CI 0.371.30) with baseline SGLT2is and 0.74 (95% CI 0.580.94) without SGLT2is ( P -value for interaction 0.70), and the HR for HHF was 0.23 (95% CI 0.050.97) with SGLT2is and 0.70 (95% CI 0.421.17) without SGLT2is ( P -value for interaction 0.35) [47]
In the UK, Wegovy tablets are currently the first GLP-1 tablet licensed for weight management in eligible adults
Your provider can give personalized guidance based on your health history
ROR = 3.44, 95% CI 3.343.55), weight loss (n = 7815
